DOCUMENT
Jul 2020 - LJF Summary of Amendments
Prepared July 2020 AG Summary of Lothian Joint Formulary Amendments The purpose of this summary is to detail the main changes to the LJF sections and provide additional information on the reasons fo...
Search Results
All Content Formulary Only Other ContentWe have found 5 results when searching "Naproxen"
DOCUMENT
23/07/2025 East Region Formulary Committee Minutes
East Region Formulary ERFC Minutes 23 July 2025 Page 1 of 13 East Region Formulary Committee Minutes Date: 23 July 2025 Time: 2.00pm – 4:20pm Location: MS Teams Present: Ruth Cameron Advanced ...
FORMULARY DECISION
Sumatriptan + Naproxen : Suvexx
The acute treatment of the headache phase of migraine attacks with or without aura in adults where treatment with a mono-entity product has been insufficient.
FORMULARY DECISION
Naproxen + Esomeprazole : Vimovo
734/11 : For the symptomatic treatment of osteoarthritis (OA), rheumatoid arthritis (RA) and ankylosing spondylitis (AS), in patients who are at risk for developing non-steroidal anti-inflammatory dru...
FORMULARY DECISION
Naproxen : Stirlescent
1154/16 : Treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, acute musculoskeletal disorders, dysmenorrhoea and acute gout in adults.